1799 related articles for article (PubMed ID: 8603820)
1. Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity.
Lilischkis R; Sarcevic B; Kennedy C; Warlters A; Sutherland RL
Int J Cancer; 1996 Apr; 66(2):249-54. PubMed ID: 8603820
[TBL] [Abstract][Full Text] [Related]
2. Mutations associated with familial melanoma impair p16INK4 function.
Ranade K; Hussussian CJ; Sikorski RS; Varmus HE; Goldstein AM; Tucker MA; Serrano M; Hannon GJ; Beach D; Dracopoli NC
Nat Genet; 1995 May; 10(1):114-6. PubMed ID: 7647780
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
Fåhraeus R; Laín S; Ball KL; Lane DP
Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
[TBL] [Abstract][Full Text] [Related]
4. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
[TBL] [Abstract][Full Text] [Related]
5. Activation of the E2F transcription factor by cyclin D1 is blocked by p16INK4, the product of the putative tumor suppressor gene MTS1.
Schulze A; Zerfass K; Spitkovsky D; Henglein B; Jansen-Dürr P
Oncogene; 1994 Dec; 9(12):3475-82. PubMed ID: 7970707
[TBL] [Abstract][Full Text] [Related]
6. Identification of functional elements of p18INK4C essential for binding and inhibition of cyclin-dependent kinase (CDK) 4 and CDK6.
Noh SJ; Li Y; Xiong Y; Guan KL
Cancer Res; 1999 Feb; 59(3):558-64. PubMed ID: 9973200
[TBL] [Abstract][Full Text] [Related]
7. Identification of CDK4 sequences involved in cyclin D1 and p16 binding.
Coleman KG; Wautlet BS; Morrissey D; Mulheron J; Sedman SA; Brinkley P; Price S; Webster KR
J Biol Chem; 1997 Jul; 272(30):18869-74. PubMed ID: 9228064
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical detection of CDK4 and p16INK4 proteins in cutaneous malignant melanoma.
Wang YL; Uhara H; Yamazaki Y; Nikaido T; Saida T
Br J Dermatol; 1996 Feb; 134(2):269-75. PubMed ID: 8746340
[TBL] [Abstract][Full Text] [Related]
9. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity.
Lukas J; Bartkova J; Rohde M; Strauss M; Bartek J
Mol Cell Biol; 1995 May; 15(5):2600-11. PubMed ID: 7739541
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and mutagenic analysis of the melanoma tumor suppressor gene product/p16.
Wick ST; Dubay MM; Imanil I; Brizuela L
Oncogene; 1995 Nov; 11(10):2013-9. PubMed ID: 7478520
[TBL] [Abstract][Full Text] [Related]
11. Two different bindings of p21 Cdk inhibitor to cyclin/Cdk complex.
Nakanishi M; Kagawa Y; Takahashi H; Matsushime H
Leukemia; 1997 Apr; 11 Suppl 3():356-7. PubMed ID: 9209388
[TBL] [Abstract][Full Text] [Related]
12. An NF-kappaB-specific inhibitor, IkappaBalpha, binds to and inhibits cyclin-dependent kinase 4.
Li J; Joo SH; Tsai MD
Biochemistry; 2003 Nov; 42(46):13476-83. PubMed ID: 14621993
[TBL] [Abstract][Full Text] [Related]
13. Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression.
Hiyama H; Iavarone A; LaBaer J; Reeves SA
Oncogene; 1997 May; 14(21):2533-42. PubMed ID: 9191053
[TBL] [Abstract][Full Text] [Related]
14. Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product.
Parry D; Bates S; Mann DJ; Peters G
EMBO J; 1995 Feb; 14(3):503-11. PubMed ID: 7859739
[TBL] [Abstract][Full Text] [Related]
15. Biochemical characterization of p16INK4- and p18-containing complexes in human cell lines.
Ragione FD; Russo GL; Oliva A; Mercurio C; Mastropietro S; Pietra VD; Zappia V
J Biol Chem; 1996 Jul; 271(27):15942-9. PubMed ID: 8663131
[TBL] [Abstract][Full Text] [Related]
16. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
[TBL] [Abstract][Full Text] [Related]
17. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano M; Hannon GJ; Beach D
Nature; 1993 Dec; 366(6456):704-7. PubMed ID: 8259215
[TBL] [Abstract][Full Text] [Related]
18. Regulation of cyclin-dependent kinase 4 during adipogenesis involves switching of cyclin D subunits and concurrent binding of p18INK4c and p27Kip1.
Phelps DE; Xiong Y
Cell Growth Differ; 1998 Aug; 9(8):595-610. PubMed ID: 9716177
[TBL] [Abstract][Full Text] [Related]
19. Interaction of retinoblastoma protein and D cyclins during cell-growth inhibition by hexamethylenebisacetamide in TM2H mouse epithelial cells.
Said TK; Medina D
Mol Carcinog; 1998 Jun; 22(2):128-43. PubMed ID: 9655257
[TBL] [Abstract][Full Text] [Related]
20. Expression of the cyclin-dependent kinase inhibitors p16INK4, p15INK4B and p21WAF1/CIP1 in human breast cancer.
Musgrove EA; Lilischkis R; Cornish AL; Lee CS; Setlur V; Seshadri R; Sutherland RL
Int J Cancer; 1995 Nov; 63(4):584-91. PubMed ID: 7591270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]